Goh E - Search Results

1

Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor.

Pasha MK, Jayaraman R, Reddy VP, Yeo P, Goh E, Williams A, Goh KC, Kantharaj E. Pasha MK, et al. Among authors: goh kc, goh e. Drug Metab Lett. 2012 Mar;6(1):33-42. doi: 10.2174/187231212800229336. Drug Metab Lett. 2012. PMID: 22372550

2

Development and validation of high-performance liquid chromatography-tandem mass spectrometry assay for 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies.

Yeo P, Xin L, Goh E, New LS, Zeng P, Wu X, Venkatesh P, Kantharaj E. Yeo P, et al. Among authors: goh e. Biomed Chromatogr. 2007 Feb;21(2):184-9. doi: 10.1002/bmc.734. Biomed Chromatogr. 2007. PMID: 17221921

3

In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.

Venkatesh PR, Goh E, Zeng P, New LS, Xin L, Pasha MK, Sangthongpitag K, Yeo P, Kantharaj E. Venkatesh PR, et al. Among authors: goh e. Biol Pharm Bull. 2007 May;30(5):1021-4. doi: 10.1248/bpb.30.1021. Biol Pharm Bull. 2007. PMID: 17473456 Free article.

4

Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.

Jayaraman R, Pilla Reddy V, Pasha MK, Wang H, Sangthongpitag K, Yeo P, Hu CY, Wu X, Xin L, Goh E, New LS, Ethirajulu K. Jayaraman R, et al. Among authors: goh e. Drug Metab Dispos. 2011 Dec;39(12):2219-32. doi: 10.1124/dmd.111.041558. Epub 2011 Aug 26. Drug Metab Dispos. 2011. PMID: 21873472

5

Diagnosing intake and rationalizing toxicities associated with 5F-MDMB-PINACA and 4F-MDMB-BINACA abuse.

Lie W, Cheong EJY, Goh EML, Moy HY, Cannaert A, Stove CP, Chan ECY. Lie W, et al. Arch Toxicol. 2021 Feb;95(2):489-508. doi: 10.1007/s00204-020-02948-3. Epub 2020 Nov 24. Arch Toxicol. 2021. PMID: 33236189

6

Urinary Metabolite Biomarkers for the Detection of Synthetic Cannabinoid ADB-BUTINACA Abuse.

Sia CH, Wang Z, Goh EML, Tan YL, Fong CY, Moy HY, Chan ECY. Sia CH, et al. Clin Chem. 2021 Nov 1;67(11):1534-1544. doi: 10.1093/clinchem/hvab134. Clin Chem. 2021. PMID: 34387654

7

Transesterification of Indazole-3-carboxamide Synthetic Cannabinoids: Identification of Metabolite Biomarkers for Diagnosing Co-abuse of 5F-MDMB-PINACA and Alcohol.

Wang Z, Fong CY, Goh EML, Moy HY, Chan ECY. Wang Z, et al. J Anal Toxicol. 2023 Jan 24;46(9):1016-1024. doi: 10.1093/jat/bkab121. J Anal Toxicol. 2023. PMID: 34918103

8

Identification of Optimal Urinary Biomarkers of Synthetic Cannabinoids BZO-HEXOXIZID, BZO-POXIZID, 5F-BZO-POXIZID, and BZO-CHMOXIZID for Illicit Abuse Monitoring.

Lee KZH, Wang Z, Fong CY, Goh EML, Moy HY, Chan ECY. Lee KZH, et al. Clin Chem. 2022 Nov 3;68(11):1436-1448. doi: 10.1093/clinchem/hvac138. Clin Chem. 2022. PMID: 36175111

9

Characterization of iso-LSD metabolism using human liver microsomes in comparison to LSD and its applicability as urinary biomarker for LSD consumption.

Ng XQ, Goh EML, Hamzah A, Yao YJ, Moy HY. Ng XQ, et al. J Anal Toxicol. 2024 Jun 11;48(5):281-288. doi: 10.1093/jat/bkae023. J Anal Toxicol. 2024. PMID: 38613436

10

Elucidating the Phase I metabolism of psilocin in vitro.

Chen J, Wang Z, Yong CY, Goh EML, Moy HY, Chan ECY. Chen J, et al. Among authors: goh eml. Arch Toxicol. 2025 Jan 3. doi: 10.1007/s00204-024-03952-7. Online ahead of print. Arch Toxicol. 2025. PMID: 39751877

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

552 results

Search Page

Filters